TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32335086

Group type: EXPERIMENTAL
Intervention: Periprostatic block
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Periapical triangle block
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Branches of perineal nerve (BPN) block
Number of subjects: 90
Study: 35761355

Group type: EXPERIMENTAL
Intervention: Cervical Collar (CC)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Manual In-line Stabilization (MILS)
Number of subjects: 32
Study: 34514891

Group type: COMPARATOR
Intervention: Group A: manual lymphatic drainage + Intermittent Pneumatic Compression + Bandages
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Group B: pneumatic lymphatic drainage + Intermittent Pneumatic Compression + Bandages
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Group C: only Intermittent Pneumatic Compression + Bandages
Number of subjects: 194
Study: 34839318

Group type: EXPERIMENTAL
Intervention: Sugammadex (2 mg/kg administered after rocuronium infusion)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (no neuromuscular blockade after induction of anesthesia)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 76
Study: 34454860

Group type: EXPERIMENTAL
Intervention: Selective intracoronary hypothermia during PPCI
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard PPCI (Control)
Number of subjects: 50
Study: 35633928

Group type: EXPERIMENTAL
Intervention: BPNN model
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: SVM model
Number of subjects: 355
Study: 33434277

Group type: EXPERIMENTAL
Intervention: Patients with co-morbidities
Number of subjects: 379
Study: 36052811

Group type: EXPERIMENTAL
Intervention: Decision aid plus telephone coaching (intervention)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 800
Study: 33493368

Group type: EXPERIMENTAL
Intervention: SYN023 (0.3 mg/kg, 1.0 mg/kg, 2.0 mg/kg) via intramuscular injection
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SYN023 (0.3 mg/kg) via subcutaneous injection
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SYN023 (0.3 mg/kg) via intramuscular or subcutaneous injection
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SYN023 (higher doses)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SYN023 (0.3 mg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: SYN023 (IM vs SC administration)
Number of subjects: 50
Study: 32432384

Group type: EXPERIMENTAL
Intervention: Multi-session CBM-I (Sentence Word Association Paradigm [SWAP] with feedback)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Control (SWAP without feedback)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 318
Study: 35113430

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Intermittent Training (MIT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low-Intensity Continuous Training (LCT)
Number of subjects: 15
Study: 34507697

Group type: EXPERIMENTAL
Intervention: Autologous platelet rich plasma
Number of subjects: 0
Study: 34932988

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting sarcopenia risk
Number of subjects: 1050
Study: 35956389

Group type: EXPERIMENTAL
Intervention: Chitosan-derived glucosamine (1500 mg glucosamine sulfate 2KCl)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biofermentation-derived glucosamine (1500 mg glucosamine sulfate 2KCl)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34320390

Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine-elicited human sera
Number of subjects: 215

Group type: COMPARATOR
Intervention: Convalescent wild-type infected serums
Number of subjects: 215

Group type: COMPARATOR
Intervention: Convalescent P.1 patients
Number of subjects: 215
Study: 35790316

Group type: EXPERIMENTAL
Intervention: Home-based inspiratory muscle training (IMT) programme for 12 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 26
Study: 33618029

Group type: EXPERIMENTAL
Intervention: 0.1% Cys fortification in low-CP diet
Number of subjects: 432

Group type: COMPARATOR
Intervention: Normal-CP diet (positive control)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Low-CP diet (negative control)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: 0.05%, 0.1%, 0.15%, 0.2% Cys fortification in low-CP diet
Number of subjects: 432
Study: 32428202

Group type: EXPERIMENTAL
Intervention: Hospital at Home (HAH)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Hospital inpatient care
Number of subjects: 34
Study: 35551149

Group type: EXPERIMENTAL
Intervention: Dolutegravir + Rilpivirine
Number of subjects: 1021

Group type: COMPARATOR
Intervention: Current Antiretroviral Regimen (CAR)
Number of subjects: 1021
Study: 33901868

Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33336508

Group type: EXPERIMENTAL
Intervention: 1% (w/w) GSK2646264
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 32897372

Group type: EXPERIMENTAL
Intervention: PREVENT QI intervention (multicomponent intervention including clinical programs, data feedback, professional education, electronic health record tools, and QI support)
Number of subjects: 1135

Group type: COMPARATOR
Intervention: Matched control sites (no intervention)
Number of subjects: 1135
Study: 33508224

Group type: EXPERIMENTAL
Intervention: 3HP (isoniazid and rifapentine) for 12 weeks
Number of subjects: 2923

Group type: COMPARATOR
Intervention: No treatment (3HP negative)
Number of subjects: 2923

Group type: EXPERIMENTAL
Intervention: RISK11-positive participants
Number of subjects: 2923

Group type: COMPARATOR
Intervention: RISK11-negative participants
Number of subjects: 2923
Study: 33222989

Group type: EXPERIMENTAL
Intervention: Team handball group (THG, n = 41)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (CG, n = 26)
Number of subjects: 67
Study: 35660103

Group type: EXPERIMENTAL
Intervention: Repetitive neuromuscular magnetic stimulation (rNMS) targeting the upper trapezius muscles (UTM)
Number of subjects: 33
Study: 36128500

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma and hyaluronic acid after arthroscopic joint debridement
Number of subjects: 126

Group type: COMPARATOR
Intervention: Arthroscopic joint debridement
Number of subjects: 126
Study: 34291957

Group type: EXPERIMENTAL
Intervention: Web-based alcohol intervention including strategies to reduce drinking and improve regulatory skills
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Web-based alcohol intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 200
Study: 35960871

Group type: EXPERIMENTAL
Intervention: Oral azacitidine (Oral‐AZA) 300 mg
Number of subjects: 472

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 472
Study: 33462358

Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35013351

Group type: EXPERIMENTAL
Intervention: BioFire FilmArray Pneumonia panel plus (FAP plus)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard diagnostic methods (SDs)
Number of subjects: 104
Study: 34158088

Group type: EXPERIMENTAL
Intervention: 4 × 4 cm onlay mesh
Number of subjects: 288

Group type: COMPARATOR
Intervention: Conventional suture repair
Number of subjects: 288
Study: 34586357

Group type: EXPERIMENTAL
Intervention: Pain Reprocessing Therapy (PRT)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 151
Study: 33865865

Group type: EXPERIMENTAL
Intervention: CRT-P (pacemaker)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CRT-D (combined pacemaker-defibrillator)
Number of subjects: 0
Study: 32240228

Group type: COMPARATOR
Intervention: Foot massager
Number of subjects: 28

Group type: COMPARATOR
Intervention: Heat therapy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Foot massager plus heat therapy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: No active intervention
Number of subjects: 28
Study: 32833539

Group type: EXPERIMENTAL
Intervention: Minoxidil + Concentrated Growth Factors (CGF)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Minoxidil
Number of subjects: 16
Study: 34289839

Group type: EXPERIMENTAL
Intervention: Face to face counseling intervention (AMI)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Peer-facilitated health campaign (three oral health fairs)
Number of subjects: 331
Study: 33280667

Group type: EXPERIMENTAL
Intervention: Plant cultivating program conducted for six weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Plant cultivating program
Number of subjects: 80
Study: 36113534

Group type: EXPERIMENTAL
Intervention: ShangRing
Number of subjects: 1378

Group type: COMPARATOR
Intervention: Mogen clamp
Number of subjects: 1378
Study: 35003318

Group type: EXPERIMENTAL
Intervention: Massive transfusion protocol
Number of subjects: 94

Group type: COMPARATOR
Intervention: Routine transfusion protocol
Number of subjects: 94
Study: 32569678

Group type: EXPERIMENTAL
Intervention: 46 µg/day TMG
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 94 µg/day TMG
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 147 µg/day TMG
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 184 µg/day TMG
Number of subjects: 80
Study: 34024220

Group type: EXPERIMENTAL
Intervention: Extracellular vesicles (EVs) in prostate cancer (PCa) patients
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Extracellular vesicles (EVs) in newly diagnosed PCa patients
Number of subjects: 16
Study: 33819140

Group type: EXPERIMENTAL
Intervention: Intravenous unfractionated heparin started 12 hours postoperatively at 10 UI/kg per hour
Number of subjects: 365

Group type: COMPARATOR
Intervention: No heparin treatment
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Heparin prophylaxis
Number of subjects: 365
Study: 35236099

Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35992545

Group type: EXPERIMENTAL
Intervention: Remazolam combined with etomidate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Etomidate (single-drug group)
Number of subjects: 100
Study: 35867146

Group type: EXPERIMENTAL
Intervention: Outpatient monitoring of IOP with self-tonometry for 7 days
Number of subjects: 1980

Group type: COMPARATOR
Intervention: Inpatient monitoring of IOP for 24 hours
Number of subjects: 1980
Study: 32498426

Group type: EXPERIMENTAL
Intervention: Test product (AA mixture engineered to prolong AA absorption with Physiomimic TechnologyTM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Reference product (free AA mixture)
Number of subjects: 30
Study: 616760951

Group type: EXPERIMENTAL
Intervention: Resident Assessment Instrument (RAI) implemented intensively
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resident Assessment Instrument (RAI) not implemented intensively
Number of subjects: 0
Study: 35470085

Group type: EXPERIMENTAL
Intervention: Half-dose photodynamic therapy (PDT) for 12 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Eplerenone for 12 weeks
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Half-dose photodynamic therapy (PDT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Eplerenone
Number of subjects: 49
Study: 33471164

Group type: EXPERIMENTAL
Intervention: Shock Wave Lithotripsy (SWL)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Laser Ureteroscopy (URS)
Number of subjects: 108
Study: 32246432

Group type: EXPERIMENTAL
Intervention: Caregiver FACT-G
Number of subjects: 747
Study: 34139706

Group type: EXPERIMENTAL
Intervention: MARS
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SPAD
Number of subjects: 20
Study: 32006516

Group type: EXPERIMENTAL
Intervention: MMR+V (combined measles-mumps-rubella-varicella vaccine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monovalent varicella vaccine
Number of subjects: 0
Study: 35867273

Group type: EXPERIMENTAL
Intervention: Propranolol (1–3 mg/kg/d, BID)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 20
Study: 34436610

Group type: EXPERIMENTAL
Intervention: ASA plus ticagrelor
Number of subjects: 6558

Group type: COMPARATOR
Intervention: ASA monotherapy
Number of subjects: 6558
Study: 36115296

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI) - 8 sessions of 90 minutes each
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 40
Study: 34114651

Group type: EXPERIMENTAL
Intervention: Immediate CASITA intervention
Number of subjects: 347

Group type: COMPARATOR
Intervention: Delayed CASITA intervention
Number of subjects: 347
Study: 96312189

Group type: EXPERIMENTAL
Intervention: Buprenorphine (6 mg i.m.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Morphine (30 mg i.m.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Naloxone (0.3 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Buprenorphine (6 mg i.m.) at 120 mg/day morphine
Number of subjects: 6
Study: 36223962

Group type: EXPERIMENTAL
Intervention: Healthy ad libitum diet with S&SE products
Number of subjects: 370

Group type: COMPARATOR
Intervention: Healthy ad libitum diet without S&SE products
Number of subjects: 370
Study: 32597466

Group type: EXPERIMENTAL
Intervention: Baricitinib plus hydroxychloroquine
Number of subjects: 15
Study: 32810387

Group type: EXPERIMENTAL
Intervention: Longer educational attainment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher math class taken
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Math ability, cognitive performance, and intelligence
Number of subjects: 0
Study: 36101802

Group type: EXPERIMENTAL
Intervention: Overall nursing intervention under the supervision of DSA
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine nursing intervention
Number of subjects: 50
Study: 33866329

Group type: EXPERIMENTAL
Intervention: Summary data‐based Mendelian randomization (SMR) method integrating GWAS and eQTL data
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Meta-analyzed version of the eQTL summary data in the brain (brain‐eMeta)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: SMR analysis
Number of subjects: 13
Study: 35991778

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral ilioinguinal and iliohypogastric nerve block
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no nerve block)
Number of subjects: 64
Study: 33316225

Group type: EXPERIMENTAL
Intervention: Overground robotic (OR) training added to ongoing rehabilitation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ongoing rehabilitation program (Control Group)
Number of subjects: 36
Study: 32989447

Group type: EXPERIMENTAL
Intervention: IV mecillinam
Number of subjects: 1129

Group type: COMPARATOR
Intervention: piperacillin/tazobactam
Number of subjects: 1129

Group type: COMPARATOR
Intervention: meropenem
Number of subjects: 1129
Study: 32146983

Group type: EXPERIMENTAL
Intervention: Wound Tracker Professional iOS compatible device
Number of subjects: 20

Group type: COMPARATOR
Intervention: Acetate tracing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aranz medical wound measuring system
Number of subjects: 20
Study: 35475793

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment for 3 consecutive weeks based on routine conventional treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine conventional treatment alone
Number of subjects: 80
Study: 32864685

Group type: EXPERIMENTAL
Intervention: Etanercept (50 mg/week)
Number of subjects: 851

Group type: COMPARATOR
Intervention: MTX (20 mg/week)
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: PASDAS (continuous composite measure)
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Continuous composite measures (DAS28-CRP, CDAI, SDAI, DAPSA, PASDAS)
Number of subjects: 851
Study: 32453997

Group type: EXPERIMENTAL
Intervention: Gait training session with body weight support (BWS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gait training using a walker without BWS
Number of subjects: 0
Study: 32638063

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) for 12 weeks
Number of subjects: 79

Group type: COMPARATOR
Intervention: PFMT plus solifenacin for 36 weeks
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 79

Group type: COMPARATOR
Intervention: PFMT plus solifenacin
Number of subjects: 79
Study: 32497454

Group type: EXPERIMENTAL
Intervention: HIIT (10 X 1-min bouts of running at 80-90% HRmax, separated by 1-min active recovery)
Number of subjects: 24

Group type: COMPARATOR
Intervention: MICT (50-min continuous jogging/brisk walking at 65-70% HRmax)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 24

Group type: COMPARATOR
Intervention: MICT
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HIIT and MICT
Number of subjects: 24
Study: 34579020

Group type: EXPERIMENTAL
Intervention: CARET + broccoli supplement (TS)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CARET + placebo (TP)
Number of subjects: 44

Group type: COMPARATOR
Intervention: control + broccoli supplement (S)
Number of subjects: 44

Group type: COMPARATOR
Intervention: control + placebo (CP)
Number of subjects: 44
Study: 33980951

Group type: EXPERIMENTAL
Intervention: BLC (bioconverted product of Lotus corniculatus seed)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 32243385

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous injection of granisetron (control)
Number of subjects: 0
Study: 36167703

Group type: EXPERIMENTAL
Intervention: Offline continuous theta‐burst transcranial magnetic stimulation (cTBS) of the DLPFC
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study: 33907133

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with western medicine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 56
Study: 34193475

Group type: EXPERIMENTAL
Intervention: rfMDA using dihydroartemisinin-piperaquine (DP)
Number of subjects: 222

Group type: COMPARATOR
Intervention: RACD involving RDTs and artemether-lumefantrine
Number of subjects: 222
Study: 32144210

Group type: EXPERIMENTAL
Intervention: Group cognitive behavioural programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35226724

Group type: EXPERIMENTAL
Intervention: Automated boluses (ropivacaine 0.2% as 8 ml every 2 h, initiated 5 h after discharge)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Continuous infusion (ropivacaine 0.2% as 6 ml/h, initiated before discharge)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Automated boluses
Number of subjects: 70

Group type: COMPARATOR
Intervention: Continuous infusion
Number of subjects: 70
Study: 32584881

Group type: EXPERIMENTAL
Intervention: Food supplementation from mid-gestation to term
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Food supplementation from pre-conception to term
Number of subjects: 236

Group type: COMPARATOR
Intervention: Non-supplemented mothers
Number of subjects: 236
Study: 34246358

Group type: EXPERIMENTAL
Intervention: CoronaVac vaccine (3 µg inactivated SARS-CoV-2 virion) administered intramuscularly on days 0 and 14
Number of subjects: 10218

Group type: COMPARATOR
Intervention: Placebo (all vaccine components except inactivated virus)
Number of subjects: 10218

Group type: EXPERIMENTAL
Intervention: CoronaVac vaccine
Number of subjects: 10218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10218
Study: 36056778

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (25 mg orally twice daily in continuous 28-day cycles)
Number of subjects: 12
Study: 33808476

Group type: EXPERIMENTAL
Intervention: Supplemented Mediterranean Diet (SMD) with 50 g/day of extra-virgin olive oil (EVOO) and 30 g/day of walnuts
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Supplemented Mediterranean Diet (SMD)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Regular diet (control group)
Number of subjects: 102
Study: 33105861

Group type: EXPERIMENTAL
Intervention: Kudzu flower and mandarin peel extract (KM) 1150 mg/day
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 35368058

Group type: EXPERIMENTAL
Intervention: Alirocumab (150 mg biweekly for 52 weeks)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 300
Study: 33323690

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32434975

Group type: EXPERIMENTAL
Intervention: Controlled-release drugs - chlorhexidine gel
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Metronidazole gel
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tetracycline fibers
Number of subjects: 60
Study: 33579349

Group type: EXPERIMENTAL
Intervention: Modified Banxia Xiexin decoction (BXD) for 3 weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 84
Study: 34797698

Group type: COMPARATOR
Intervention: 35% phosphoric acid
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (200 mJ, 30 Hz)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (250 mJ, 30 Hz)
Number of subjects: 81
Study: 34918443

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg.kg-1)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Propofol (1 mg.kg-1)
Number of subjects: 53
Study: 32333434

Group type: EXPERIMENTAL
Intervention: Televised alcohol advertising exposure
Number of subjects: 54671
Study: 35789991

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (60,000 international units monthly for 5 years)
Number of subjects: 20334

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (60,000 international units monthly for 5 years) in adults aged ≥70 years
Number of subjects: 20334
Study: 33372392

Group type: EXPERIMENTAL
Intervention: Vitamin D 1000 IU and Calcium 1000 mg daily for 6 weeks (Group A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Vitamin D 250 IU and Calcium 500 mg daily for 6 weeks (Group B)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 32414298

Group type: COMPARATOR
Intervention: 100% adherence to placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0% adherence to placebo
Number of subjects: 0
Study: 34496115

Group type: EXPERIMENTAL
Intervention: Transplant center-based outreach intervention
Number of subjects: 103